Margo Warren joins panel for UICC Special Focus Dialogue on AMR

Cancer patients, who undergo therapies that can compromise their immune systems, are particularly susceptible to contracting bacterial infections, making effective antibiotics vital in supporting them during their treatment regimens. However, the rapid rise of drug-resistant pathogens (or superbugs) threatens the efficacy of current antimicrobial products, including antibiotics, necessitating the urgent development of new medicines that can overcome drug-resistant infections. 

The virtual dialogue hosted by UICC will focus on current shortfalls in R&D efforts to create new antimicrobial drugs, as well as the need to ensure sustainable, widespread access to these products after market approval. 

During the event, Margo will participate in a panel discussion focused on how to reinvigorate the R&D pipeline to address AMR alongside other experts, including: 

• Greg Frank, Director of Global Public Policy, MSD 

• Henry Skinner, CEO, AMR Action Fund 

• Lesley Ogilvie, Director, Global AMR R&D Hub Secretariat 

Margo will share research insights from the Foundation’s AMR Programme, including the 2021 AMR Benchmark report and the recently published paper on antimicrobial R&D, entitled “How can pharma get the few promising drugs in development to patients battling superbugs?”